SEC Form 4 · accession 0001708138-17-000003
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael S Brown
Director
Period of report
Jun 12, 2017
Accepted (ET)
Jun 14, 2017 · 4:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 12, 2017 | M | 2,000 | $177.82 | A | 2,000 | D | |
| Common Stock | Jun 12, 2017 | S | 100 | $472.04 | D | 1,900 | D | |
| Common Stock | Jun 12, 2017 | S | 100 | $477.05 | D | 1,800 | D | |
| Common StockF2 | Jun 12, 2017 | S | 94 | $469.02 | D | 1,706 | D | |
| Common StockF3 | Jun 12, 2017 | S | 200 | $473.37 | D | 1,506 | D | |
| Common StockF4 | Jun 12, 2017 | S | 900 | $474.37 | D | 606 | D | |
| Common StockF5 | Jun 12, 2017 | S | 606 | $475.72 | D | 0 | D | |
| Common Stock | holding | — | — | — | 17,349 | I | by Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F6 | $177.82 | Jun 12, 2017 | M | 2,000 | D | — | Jan 2, 2023 | Common Stock | 2,000 | 6,000 | D |
Explanation of responses
- F1Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- F2Represents volume-weighted average price of sales of 94 shares of Company stock on June 12, 2017 at prices ranging from $469.02 to $469.05. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 12, 2017 at each separate price.
- F3Represents volume-weighted average price of sales of 200 shares of Company stock on June 12, 2017 at prices ranging from $473.36 to $473.38. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 12, 2017 at each separate price.
- F4Represents volume-weighted average price of sales of 900 shares of Company stock on June 12, 2017 at prices ranging from $474.01 to $474.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 12, 2017 at each separate price.
- F5Represents volume-weighted average price of sales of 606 shares of Company stock on June 12, 2017 at prices ranging from $475.65 to $475.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 12, 2017 at each separate price.
- F6The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.